Luminex-based C1qScreen assay differentiates complement-binding from non-complement-binding HLA antibodies, supporting improved immunological risk stratification in transplant patients.

Magnetic bead-based assays for isolating specific HLA antibodies, enabling targeted adsorption and elution to enhance antibody identification and transplant risk assessment.

Flow cytometry-based crossmatch assay combining cellular analysis with microbead specificity for sensitive detection of leukocyte antibodies in transplant compatibility testing.

Frozen lymphocyte panels in Terasaki trays for complement-dependent cytotoxicity assays, enabling PRA determination and HLA antibody screening by traditional serological methods.

LABScreen Autoantibody assays use Luminex single antigen beads to detect and monitor diverse autoantibodies in human serum for transplant and autoimmune research.

Comprehensive antibody screening, identification, and DSA monitoring using Luminex xMAP technology to support pre- and post-transplant risk assessment.

FlowPRA assays for detecting HLA antibodies via flow cytometry, enabling PRA screening and antibody specificity assignment for Class I and Class II antigens.

ELISA assays for detecting anti-AT1R and anti-ETAR antibodies, aiding in the evaluation of non-HLA immune responses linked to graft injury and rejection.

Cost-effective ELISA trays pre-coated with HLA Class I and II antigens for screening, PRA determination, and antibody identification in transplant candidates.